Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | GJB2 | P29033 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910764 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL8017553 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL6565021 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL1134697 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4803964 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4351721 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL23646744 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4595842 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL10715427 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL3389904 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119139931-B | Preparation method of efficient boron-removing reverse osmosis membrane | 山东纳飞博科技发展有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119139931-A | Preparation method of efficient boron-removing reverse osmosis membrane | 山东纳飞博科技发展有限公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-4397374-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | Mederis Diabetes, LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11911447-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES LLC (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3155017-B1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-4286400-A2 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-2709645-B1 | IMPROVED PEPTIDE PHARMACEUTICALS | EUMEDERIS PHARMACEUTICALS INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230218564-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | MEDERIS DIABETES LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11541028-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | ALTIMMUNE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3444281-B1 | IMPROVED PEPTIDE PHARMACEUTICALS | EUMEDERIS PHARMACEUTICALS INC (US) | 2021-11-03 | — | — | EP | disclosed |
| WO-2012158965-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES, LLC (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158964-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR OSTEOPOROSIS | EUMEDERIS PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| US-8137975-B2 | Method for a rapid antibody-based analysis of platelet populations | BECKMAN COULTER, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-7674598-B2 | Method for a fully automated monoclonal antibody-based extended differential | BECKMAN COULTER, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20090111118-A1 | METHOD FOR A RAPID ANTIBODY-BASED ANALYSIS OF PLATELET POPULATIONS | BECKMAN COULTER, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2008002745-A2 | METHOD FOR A FULLY AUTOMATED MONOCLONAL ANTIBODY-BASED EXTENDED DIFFERENTIAL | BECKMAN COULTER, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20060269970-A1 | Method for a fully automated monoclonal antibody-based extended differential | BECKMAN COULTER, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| EP-0378710-A1 | Process for the preparation of alkyl glycosides | UNILEVER N.V. (NL) | 1990-07-25 | — | — | EP | disclosed |
| EP-0187798-A1 | PROCESS FOR THE SYNTHESIS OF ALDOSIDES OR OLIGOALDOSIDES OF ALKYL, CYCLOALKYL OR ALKENYL. | BEGHIN SAY SA (FR) | 1986-07-23 | — | — | EP | disclosed |
| WO-1986000906-A1 | PROCESS FOR THE SYNTHESIS OF ALDOSIDES OR POLYALDOSIDES OF ALKYL, CYCLOALKYL OR ALKENYL | BEGHIN-SAY SA (FR) | 1986-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911447-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, PTMS | GBA1 2974/4885SLC2A1 125/4885MAPK1 2392/4885 |
| US-20230218564-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | GLP1R, IAPP, GPR119 | GBA1 3581/4885SLC2A1 269/4885MAPK1 3386/4885 |
| US-11541028-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | GLP1R, IAPP, GPR119 | GBA1 3581/4885SLC2A1 269/4885MAPK1 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.